Structure Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | |
| · · DECEMBER 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets | | | | | | |
| Current assets: · · · · | ||||||
| Cash and cash equivalents | | $799,623 | | $169,510 | ||
| Short-term investments | | 646,574 | | 714,008 | ||
| Other receivable | | | 100,000 | | | — |
| Prepaid expenses and other current assets | | 24,106 | | 7,693 | ||
| Total current assets | | 1,570,303 | | 891,211 | ||
| Property and equipment, net | | 6,653 | | 3,478 | ||
| Operating right-of-use assets | | 6,245 | | 3,535 | ||
| Other non-current assets | | 717 | | 5,106 | ||
| Total assets | | $1,583,918 | | $903,330 | ||
| Liabilities and shareholders’ equity | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $13,864 | | $8,024 | ||
| Accrued expenses and other current liabilities | | 46,543 | | 26,299 | ||
| Operating lease liabilities, current portion | | 2,878 | | 1,698 | ||
| Total current liabilities | | 63,285 | | 36,021 | ||
| Operating lease liabilities, net of current portion | | | 3,609 | | | 2,164 |
| Other non-current liabilities | | | 647 | | | 302 |
| Total liabilities | | 67,541 | | 38,487 | ||
| Commitments and contingencies (Note 5) | | | | | ||
| Shareholders’ equity: | | | | | ||
| Undesignated shares – $0.0001 par value; 100,000 shares authorized as of December 31, 2025 and December 31, 2024 | | | — | | | — |
| Ordinary shares – $0.0001 par value; 500,000 shares authorized as of December 31, 2025 and December 31, 2024; 212,513 and 171,860 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | | 21 | | 17 | ||
| Additional paid-in capital | | 1,985,602 | | 1,193,010 | ||
| Accumulated other comprehensive income | | 1,054 | | 914 | ||
| Accumulated deficit | | (470,300) | | (329,098) | ||
| Total shareholders’ equity | | 1,516,377 | | 864,843 | ||
| Total liabilities and shareholders’ equity | | $1,583,918 | | $903,330 | ||
| | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.